Alterations in creatine kinase, phosphate and lipid values in patients with chronic myeloid leukemia during treatment with imatinib.
Imatinib, the treatment of choice for chronic myeloid leukemia, is generally well tolerated. We present here data from a retrospective analysis on metabolic abnormalities occurring during therapy which show increased creatine kinase, inverse creatine kinase-phosphate correlation, cholesterol and triglyceride values.
Franceschino
Anna
A
Tornaghi
Lucia
L
Benemacher
Valerie
V
Assouline
Sarit
S
Gambacorti-Passerini
Carlo
C
D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects*; D001549:Benzamides; D003402:Creatine Kinase / Q000378:metabolism*; D005260:Female; D006801:Humans; D000068877:Imatinib Mesylate; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000150:complications* / Q000188:drug therapy / Q000378:metabolism; D050356:Lipid Metabolism / Q000187:drug effects*; D008297:Male; D008659:Metabolic Diseases / Q000139:chemically induced* / Q000378:metabolism; D008875:Middle Aged; D010710:Phosphates / Q000378:metabolism*; D010879:Piperazines / Q000008:administration & dosage / Q000009:adverse effects*; D011743:Pyrimidines / Q000008:administration & dosage / Q000009:adverse effects*; D012189:Retrospective Studies
D000970:Antineoplastic Agents; D001549:Benzamides; D010710:Phosphates; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate; D003402:Creatine Kinase